Introduction {#Sec1}
============

Since Emil Kraepelin's conceptualization of endogenous psychoses as two categories, dementia praecox and manic depression, the separation between primary psychotic disorders and primary affective disorders has been much debated.^[@CR1]--[@CR4]^ There is substantial evidence that these illnesses share genetic risk factors and overlap in clinical presentation and treatments, suggesting these clinical phenotypes to be on a disease continuum or even differential expressions of the same illness.^[@CR5]^ Contemporary models attempt to move towards classification of psychiatric disorders based on etiologic and pathophysiologic processes, integrating complex relationships between genetics, physiology, and behavior.^[@CR6],\ [@CR7]^

Since the initial description of the principles of magnetic resonance imaging (MRI) by Paul Lauterbur in 1973^[@CR8]^ and the first human MRI scan in 1977,^[@CR9]^ much progress has been made in the field of neuroimaging. A variety of contemporary non-invasive sequences are now available to aid structural, functional, and neurochemical characterization of the human brain, providing new opportunities to shed light on biological and pathological processes in vivo.^[@CR10]^

Conventional, T1-weighted, structural MRI images provide static anatomical information with excellent detail and strong gray/white matter contrast. Manual tracing methods examine brain morphology of pre-defined regions of interest (ROI) such as the hippocampus, but are quite labor intensive. Computational advances offer semi-automated and automated alternatives to manual tracings. One of the most popular automated techniques is voxel-based morphometry (VBM^[@CR11]^), which quantifies brain structure at the voxel level, with a typical resolution of 1 mm^3^. Another frequently used automated structural imaging analysis technique is Free Surfer,^[@CR12]^ which also examines cortical thickness, cortical gyrification, and shapes of sub-cortical structures. Diffusion weighted imaging techniques, such as diffusion tensor imaging (DTI), map three dimensional motion of water as a function of spatial location to describe anatomy of anisotropic tissues such as white mater.^[@CR13]^ The most widely reported diffusion tensor measures are fractional anisotropy (FA) and mean diffusivity (MD) which describe complementary information on structural white matter integrity. Tract based spatial statistics (TBSS) is an automated method describing diffusion metrics from white matter in the entire brain,^[@CR14]^ whereas fiber tracking quantitatively assess the microstructure of a specific white matter tract.^[@CR15]^ Fiber reconstruction methods are either deterministic or probabilistic; deterministic methods follow the primary eigenvector from voxel to voxel in three dimensions, whereas probabilistic methods incorporate expected uncertainty into the algorithm.^[@CR16]^

Functional MRI (fMRI) imaging provides dynamic physiological information by measuring the blood oxygen level dependent (BOLD) signal.^[@CR17]^ Task fMRI characterizes brain activity while subjects perform cognitive tasks by measuring changes in the BOLD signal in different areas of the brain. In block designs different conditions are alternated in blocks, where the condition assessing the cognitive process of interest is alternated with a control condition, which makes in the change in the fMRI signal in response to the stimulus additive.^[@CR18]^ Block designs offer considerable statistical power, but are prone to signal drift and run the risk of having subjects become aware of the order of events. On the other hand, event related designs are more reflective of the real world, but come at the expense of statistical power.^[@CR19]^ Alternatively, resting state fMRI measures the temporal covariance of low frequency fluctuations of the BOLD signal across spatially disparate areas while no explicit task is performed, in an effort to assess the brain's intrinsic functional organization.^[@CR20]^ Seed based analysis is a popular hypothesis-driven method to visualize resting state networks.^[@CR21]^ In this case, an area of interest is defined from which correlations in BOLD fluctuations with all other voxels in the brain are calculated, allowing to examine connectivity of a specific ROI. In contrast, independent component analysis (ICA) is a data-driven method that decomposes the multivariate signal across the brain into statistically independent components (either spatially or temporally) reflecting resting state networks.^[@CR22],\ [@CR23]^

Magnetic resonance spectroscopy (MRS) measures chemical composition of tissues, energy metabolism, and neurotransmitter levels in vivo.^[@CR24]^ The most common type of spectroscopy leverages the signal produced by protons located in the molecules of living tissue to quantify different metabolites (^1^H-MRS). Metabolites that can be measured include N-acetyl-aspartate (NAA), a putative marker of neuronal integrity, choline (Cho), a marker of cellular turnover and cell membrane breakdown, creatine (Cr), a signal that is related to phosphate metabolism, and the amino acids glutamate (Glu), glutamine (Gln), often expressed as Glx (glutamate + glutamine), and ɣ-amino-butyric acid (GABA).^[@CR25]^ Other spectroscopy techniques include ^31^Phosphorus spectroscopy, which provides a wide range of information on energy metabolism, and ^13^Carbon spectroscopy which use cerebral glucose metabolism to assess glutamine synthesis and glutamatergic transmission.

These complementary imaging techniques have been applied to better delineate the neurobiology of psychiatric disorders in vivo. Structural gray and white matter deficits, as well as neurometabolite alterations, and BOLD signal abnormalities during task and at rest have been found in schizophrenia and bipolar disorder (BD). However, it remains unclear to what extent neural signatures are converging or distinct.

Here, we conducted a systematic review of case--control studies contrasting structural, functional, and neurochemical abnormalities in BD, schizoaffective disorder, schizophrenia, and healthy controls conducted in the past 10 years with the objective to summarize progress made in the quest to better delineate pathophysiological patterns across the psychosis spectrum. Where relevant, selected older publications considered key developments within the field and meta-analyses using quantitative methods to synthesize the literature are also included.

Results {#Sec2}
=======

Study identification {#Sec3}
--------------------

Figure [1](#Fig1){ref-type="fig"} describes outcomes at each level of our study identification process. Of the 394 potentially relevant articles, we included 50 structural, 29 functional, seven MRS, and eight combined imaging and genetic studies in this systematic review.Fig. 1Process of study selection

Structural MRI studies {#Sec4}
----------------------

### Gray matter structural MRI {#Sec5}

Gray matter has been an early focus of neuroimaging research in psychiatric illnesses. Using anatomical likelihood estimation (ALE), a meta-analysis of 37 studies demonstrated extensive gray matter deficits in frontal, limbic and subcortical deficits in schizophrenia when compared to healthy controls.^[@CR26]^ Similarly gray matter reductions were found in anterior cingulate and insula in an ALE meta- analysis of patients with BD when compared to healthy controls.^[@CR27]^ A recent analyses attempting to quantitatively, albeit not directly, contrast gray matter deficits in a number of psychiatric disorders, including schizophrenia and BD, using meta-analytic techniques found shared decrease in the dorsal anterior cingulate and anterior insula, areas of the brain that are attributed to the salience networks.^[@CR28]^

Forty studies explicitly examined differences in gray matter across the psychosis spectrum since 2005, but only seventeen of those were conducted at magnetic field strengths of 3T. All but one study included subjects who were medicated at the time of scanning, and only a minority of studies focused on first episode patients (Table [1](#Tab1){ref-type="table"}). Cortical gray matter volume loss appears widespread in schizophrenia, but less extensive^[@CR29]--[@CR31]^ or even absent^[@CR32],\ [@CR33]^ in BD. It has been suggested as an intermediate phenotype across disease categories, possibly reflecting lifetime psychosis burden, with patients diagnosed with schizophrenia and schizoaffective disorder demonstrating extensive neocortical and subcortical gray matter reductions, and smaller reductions limited to frontotemporal regions in BD.^[@CR29]^ Further supporting this concept is a recent study by Song et al. who examined gray matter volumes in unmedicated patients with schizophrenia and BD and reported a negative correlation between severity of delusions and frontal gray matter volumes as well as extent of hallucinations and right uncus gray matter volume across diagnostic groups.^[@CR34]^ Examining subcortical areas of the brain, studies consistently suggest that hippocampal volume reduction may be a feature that is shared across the psychosis spectrum,^[@CR35]--[@CR37]^, with a majority of studies reporting that volume loss is greater in schizophrenia compared to BD,^[@CR38]^ even when examining individual hippocampal subfields.^[@CR35],\ [@CR39]^ Similarly, early studies suggest thalamus volume reductions to be present across disease categories,^[@CR36],\ [@CR40]^ but later reports with larger sample sizes detected this feature only in schizophrenia.^[@CR29],\ [@CR41]^ Findings are more inconsistent in regards to amygdala volume, which has been reported to be unaffected in both diagnostic groups,^[@CR42],\ [@CR43]^ decreased only in schizophrenia,^[@CR44]^ more prominently decreased in schizophrenia compared than in BD^[@CR45]^ and vice versa.^[@CR37]^ Reports on basal ganglia volumes are also conflicting where some find volume increase^[@CR46],\ [@CR47]^ or decrease^[@CR48],\ [@CR49]^ that is shared across illnesses, abnormalities in schizophrenia but not BD,^[@CR34],\ [@CR36]^ or lack of abnormalities in either diagnostic group (except for the nucleus accumbens).^[@CR50]^ Those contrasting reports likely reflect the heterogeneity across studies in regards to patient characteristics, medication exposure, data acquisition, and data analysis methods.Table 1Studies examining gray matterAuthorYearn (HC/SZ/SAD/BD)Bipolar subtypeIllness durationMedication statusAreas of interestAnalysis methodTeslaMain findingsFarrow *et al.* ^[@CR113]^200522/25/0/8PFEmedicatedWhole brainVBM1.5HC \> SZ in lateral and medial frontal and posterior temporal regions. HC \> BD inferior temporal gyri and ACCStrasser *et al.* ^[@CR114]^200544/33/0/38PChronicMedicatedCerebral volume, hippocampusMEASURE, ROI (manual tracing)1.5HC = BD = SZ in cerebral volume and hippocampus volumeMc Donald *et al.* ^[@CR115]^200654/42 SZ/38PChronicMedicatedWhole brainMEASURE1.5HC = BD = SZ in cerebral volume. HC = BD \> SZ in hippocampusSalisbury *et al.* ^[@CR116]^200732/20/0/21PFEMedicatedHeschl gyriROI (manual tracing)1.5SZ \< HC = BD in left heschl gyrus gray matter volumesNakamura *et al.* ^[@CR117]^200736/29/0/34PFEMedicatedNeocortexROI (manual tracing)1.5HC \> SZ = BD neocortical gray matter volumesMorgan *et al.* ^[@CR118]^200758/44/0/29PFEMedicatedWhole brainVBM1.5No group differencesFrazier *et al.* ^[@CR42]^200829/20/0/54P/NPChronicMedicatedSubcortical volumesROI (manual tracing)1.5No group differences in hippocampus and amygdala volumesKoo *et al.* ^[@CR52]^200840/39/0/41PFEMedicatedCingulate gyrusROI (manual tracing)1.5HC \> SZ in subgenual, anterostratal, anterodorsal, and posterior subregions. HC \> BD in the subgenual subregionKillgore *et al.* ^[@CR43]^200920/19/0/11Acute psychosisMedicatedCerebrum, amygdala, hippocampusROI (manual tracing)1.5SZ \< BD = HC total brain volume, SCZ = HC = BD in amygdala and hippocampus volumeReite *et al.* ^[@CR119]^201089/58/26/51ChronicMedicatedWhole brainmanual tracing and semiautomated1.5/3No group differencesMolina *et al.* ^[@CR48]^201124/38/0/19P/NPChronicMedicatedWhole brainVBM1.5No differences in SZ vs BD. SZ \< HC in medial frontal lobe and basal ganglia. BD \< HC in medial frontal lobe and caudateRimol *et al.* ^[@CR33]^2011207/142/31/139ChronicMedicatedCortical volumeFree Surfer1.5SZ \< BD in temporal lobe, fusiform and parahippocampal gyrus. BD = HC in cortical volume. Cortical thinning seen in SZ onlyHartberg *et al.* ^[@CR36]^2011192/101/16/121ChronicMedicatedSubcortical volumesFree Surfer1.5HC \> SZ = BD hippocampus, left thalamus, SZ \> BD = HC putamen; HC \> BD in cerebellumBrown *et al.* ^[@CR37]^201121/17/0/15ChronicMedicatedWhole brain, hippocampus, amygdalaVBM1.5HC \> SZ and BD in frontotemporal regions. HC \> SZ \> BD in amygdala and right hippocampusRadonic *et al.* ^[@CR120]^201115/15/15/15ChronicMedicatedHippocampusROI (manual tracing)2SZ = SAD \< HC = BD in hippocampal volumede Castro-Manglano *et al.* ^[@CR51]^201120/10/0/14PFEMedicatedWhole brainVBM1.5HC \> BD in frontal lobe, thalamus, superior temporal gyrus, cerebellum; HC \> SZ frontal lobe, thalamus, hippocampus; BD \> SZ hippocampusCui *et al.* ^[@CR47]^201136/24/0/24PAcutely ill FE and chronicMedicatedWhole brainVBM3HC \> SZ in superior temporal and inferior parietal lobe, HC \< SZ in putamen; HC \> BD in superior temporal, inferior parietal lobe, and caudate; HC \< BD in putamenIvleva *et al.* ^[@CR49]^201210/19/16/17PChronicMedicatedWhole brainVBM, Free Surfer3HC \> SZ and SAD in frontal, temporal and insular cortices, HC \> SZ across neocortex, thalamus, and basal ganglia, BD = HC in cortical and subcortical gray matter volumeYuksel *et al.* ^[@CR32]^201243/37/21/28PChronicMedicatedWhole brainVBM3HC \> SZ in prefrontal and temporal cortices, HC \< SZ in cerebellum, BD \> SZ in subgenual cortexWatson *et al.* ^[@CR40]^201259/25/0/24PFEMedicatedWhole brainVBM1.5HC \> SZ in hippocampus, thalamus, striatum and cerebellum. HC \> BD in precuneus; BD \> HC in cerebellumMahon *et al.* ^[@CR44]^201227/31/0/36PChronicMedicatedAmygdalaFree Surfer1.5Amygdala volume SZ \< BD = HCIvleva *et al.* ^[@CR29]^2013200/146/90/115PChronicMedicatedWhole brainVBM3HC \> SZ and SAD in frontal, temporal and insular cortices, thalamus, basal ganglia, and cerebellum. HC \> BD frontal, insular, temporal and parietal cortexRatnanather *et al.* ^[@CR121]^201327/31/0/36ChronicMedicatedSTG and planum temporaleROI1.5HC = BD \> SZ in planum temporaleWomer *et al.* ^[@CR50]^201427/28/4/33P/NPChronicMedicatedSubcortical gray matterFree Surfer3HC = SZ = BP in caudate, putamen, nucleus accumbens, thalamus. BP \< HC \< SZ in globus pallidusHaukvik *et al.* ^[@CR39]^2014300/182/28/192ChronicMedicatedHippocampusFree Surfer1.5HC \> SZ in all hippocampal subfields, HC \> BD in all subfields except for the presubiculum. BD \> SZ in presubiculum and subiculumMathew *et al.* ^[@CR35]^2014337/219/142/188PChronicMedicatedMedial temporal lobeFree Surfer3BD = HC \> SZ and SAD in medial temporal cortex volume, SZ \< BD \< HC in hippocampal subfieldsKnochel *et al.* ^[@CR38]^201421/21/0/21ChronicMedicatedHippocampusVBM3Hippocampal volume HC \> BD \> SZFindikili *et al.* ^[@CR122]^201530/17/0/17ChronicMedicatedPineal glandROI (manual tracing)1.5Mean pineal gland volume SZ \< BD \< HCNenandic *et al.* ^[@CR41]^201534/34/0/17PChronicMedicatedWhole brainVBM3HC \> SZ prefrontal cortex and insula, temporal cortex, thalamus, and cerebellum. SZ \< BD in hippocampus, DLPFC, and cerebellumKittel-Schneider *et al.* ^[@CR45]^201518/23/0/30P/NPFEMedicatedAmygdalaROI (manual tracing)1.5HC \> BD \> SZ in amygdala volumeLaidi *et al.* ^[@CR123]^201552/32/0/115P/NPChronicMedicatedCerebellumFree Surfer3SZ \< HC = BD in cerebellar volumeSong *et al.* ^[@CR34]^201535/71/0/44PChronicOff medicationWhole brainVBM3HC \> SZ precentral gyrus, caudate, and cerebellum; HC \> BD middle frontal gyrus, fusiform gyrus; BD \> SZ cerebellum, temporal lobe, basal gangliaPina-Camacho *et al.* ^[@CR53]^2015157/92/0/32/72PFEMedicatedWhole brainVBM, Free Surfer1.5/3HC \> SZ in frontal and temporal lobe, SZ \> HC in basal ganglia. HC \> BD ACC, BD \> HC in caudate and temporal lobe thicker temporal cortexShepherd *et al.* ^[@CR124]^201534/28/12/30ChronicMedicatedWhole brainVBM3HC \> SZ in hippocampus and frontal cortex. HC \> BD in precuneus, superior parietal and postcentral gyrus. SZ = BD in GM volumeAmann *et al.* ^[@CR125]^201545/45/45 /45P/NPMixedMedicatedWhole brainVBM1.5HC \> SZ and SAD in anterior cingulate, insula, temporal lobe, cerebellum; HC  = BDRoyer *et al.* ^[@CR126]^201563/31/0/20ChronicMedicatedWhole brain gray matter asymmetryIn house processing3No group differencesPoletti *et al.* ^[@CR31]^2016136/96/0/206ChronicMedicatedWhole brainVBM3HC \> SZ in inferior frontal gyrus, thalamus, insula and superior temporal gyrus; HC \> BD inferior frontal gyrus; BD \> SZ thalamusReavis *et al.* ^[@CR127]^201630/33/0/31NPChronicMedicatedLateral occipital complex and retinotopic visual cortexROI3HC \>BD\>SZ in retinotopic cortex and lateral occipital complexKnoechel *et al.* ^[@CR128]^201638/32/0/34NPChronicMedicatedWhole brainFree Surfer3HC \> BD = SZ in cortical thickness in inferior frontal gyrus, ACC, PCC. HC \> SZ in dorsal frontal and temporal areas. HC \> BD in orbitofrontal cortexNenadic *et al.* ^[@CR129]^201638/32/0/34PChronicMedicatedWhole brainFree Surfer3BD \> HC in local gyrification in ACC and DLPFC, SZ \> HC in local gyrification in MPFC and orbitofrontal cortex, BD \> SZ in ACC gyrification*HC* healthy control, *BD* bipolar disorder, *SZ* schizophrenia, *SAD* schizoaffective disorder, *P* psychotic bipolar disorder, *NP* non-psychotic bipolar disorder, *FE* first episode, *VBM* voxel based morphometry, *ROI* region of interest analysis, *ACC* anterior cingulate cortex, *PCC* posterior cingulate cortex, *DLPFC* dorsolateral prefrontal cortex, *MPFC* medial prefrontal cortex, *STG superior temporal gyrus*

Significant cortical and subcortical volume loss that resembles the chronic illness stage is already reported in first episode patients. While many of the areas with gray matter loss appear to overlap across diagnostic groups, several reports suggest greater abnormalities in first episode schizophrenia compared to first episode BD, both in terms of volume loss^[@CR45],\ [@CR51]^ and spatial extent.^[@CR40],\ [@CR52]^ It is perhaps not surprising that Pina-Camacho et al. reported that age at first onset of psychosis modulated structural abnormalities in a nonlinear and diagnosis dependent manner. Specifically, they report that patients with an earlier onset of a schizophrenia spectrum disorder had the most significant ventricular and basal ganglia enlargement along with the greatest fronto-temporal cortical volume and thickness deficits among diagnostic groups, with affective disorder patients having less extensive cortical deficits that were again more prominent in those with younger age of onset of psychosis.^[@CR53]^ However, none of the studies examined medication naïve patients, making it impossible to definitively conclude that observed group differences in gray matter abnormalities are due to intrinsic differences across the diagnostic spectrum rather than secondary to differential exposure to psychotropic medications.

### White matter structural MRI {#Sec6}

White matter abnormalities have been reported to be widespread in both schizophrenia and BD. An activation likelihood estimation meta-analysis showed decreased FA in first episode schizophrenia compared to healthy controls across the commissural, association, and projection tracts, with main involvement of the inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, cingulum bundle, and corpus callosum.^[@CR54]^ Similarly, a meta-analysis of fifteen DTI studies in BD reported decreased FA in all types of tracts when compared to healthy controls, with the most robust decreases in the inferior fronto-occipital fasciculus.^[@CR55]^ Findings suggest a shared spatial distribution of white matter integrity deficits across the illness spectrum, but allow no inference on the comparability in magnitude of abnormalities.

Eleven studies contrasted white matter integrity in schizophrenia and BD; all but one included patients who were medicated at the time of assessment, and only two focused on first episode patients (Table [2](#Tab2){ref-type="table"}). It is striking that the majority of studies conducted in chronic patients on psychotropic medications show decreases in white matter integrity that do not appear different across diagnostic groups. Region of interest analyses show shared FA decreases in the uncinate fasciculus, corona radiata, anterior limb of the internal capsule, anterior and posterior thalamic radiation, and corpus callosum.^[@CR56]--[@CR60]^ This is also corroborated by Skudlarski and colleagues who conducted the largest study thus far and found a close agreement between spatial distributions and magnitudes in FA reductions assessed with whole brain TBSS across diagnostic groups. Interestingly, they reported higher variance in patients with psychotic BD, suggestive of greater heterogeneity in white matter integrity abnormalities compared to patients with schizophrenia.^[@CR61]^ Heterogeneity may also explain discrepancies with Anderson and colleagues who found FA reductions in temporal and occipital white matter in schizophrenia but not bipolar I disorder,^[@CR62]^ and Knoechel and colleagues who report that the magnitude of white matter integrity abnormalities in the left cingulum and right uncinate fasciculus is greater in schizophrenia than BD.^[@CR38]^ Table 2Studies examining white matterAuthorYearn (HC/SZ/ SAD/BD)Bipolar subtypeIllness durationMedication statusArea of interestTeslaDirect-ionsAnalysis typeMain findingsMcIntosh200849/25/0/40ChronicMedicatedUncinate fasciculus and anterior thalamic radiation1.551TractographyHC \> BD and SZ in FA in the uncinate fasciculus and anterior thalamic radiationSussmann *et al.* ^[@CR59]^200938/28/0/42ChronicMedicatedUncinate fasciculus and internal capsule1.551ROI analysesHC \> BD = SZ in FA in internal capsule, HC \> BD in anterior limb of internal capsuleCui *et al.* ^[@CR130]^201130/25/0/18PChronicMedicatedWhole brain315Voxel based analysisHC \> SZ = BD in FA in posterior corona radiata, HC \> BD in FA in fronto-parietal white matterLu *et al.* ^[@CR64]^201118/21/0/13PFEMinimally treated/ medication naïveWhole brain327VBMHC \> BP = SZ in MD in cingulum, corpus callosum, corona radiata, internal capsule, and occipital WM including posterior thalamic radiation, inferior longitudinal fasciculus/inferior fronto-occipital fasciculus. HC = SZ \> BD in FA in multiple commissural, projection, and association tractsSui *et al.* ^[@CR57]^201162/54/0/48ChronicMedicatedWhole brain312TractographyHC \> BD and SZ in FA in occipital and frontal lobesda Cunha Colombo *et al.* ^[@CR63]^201294/55/7/26PFEMedicatedWhole brain1.5VBMHC = SZ = BD in regional WM volumeAnderson *et al.* ^[@CR62]^201356/35/0/20P/NPChronicMedicated21 regions1.525ROI analysesHC = BD \> SZ in FA in superior temporal, parahippocampal, and occipital white matter; HC \< BD = SZ in MD in superior temporal, parahippocampal, inferior frontal, fusiform, angular white matter; BD \> SZ in MD precentral and middle frontal cortexSkudlarski *et al.* ^[@CR61]^2013104/109/35/63PChronicMedicatedWhole brain332TBSSHC \> SZ = BD in FA in 29 of 76 regions analyzedKnochel *et al.* ^[@CR38]^201421/21/0/21ChronicMedicatedUncinate fasciculus, cingulum, fornix360TBSSHC = BD \< SZ in MD in the cingulum; HC \> SZ = BD in MD in the fornixLi *et al.* ^[@CR60]^201424/19/0/16ChronicMedicatedCorpus Callosum325ROI analysesHC \> SZ in entire corpus callosum, HC \> BD in all subregions except the middle genuKumar *et al.* ^[@CR56]^201541/34/6/22PChronicMedicatedWhole brain332TBSS/ TractographyHC \> SZ = BD in FA in corpus callosum, corona radiata*HC* healthy control, *BD* bipolar disorder, *SZ* schizophrenia, *SAD* schizoaffective disorder, *P* psychotic bipolar disorder, *NP* non-psychotic bipolar disorder, *FE* first episode, *TBSS* tract based spatial statistics, *ROI* region of interest, *FA* fractional anisotropy, *MD* mean diffusivity, *WM* white matter

In first episode patients, no white matter volume abnormalities or no differences across diagnostic groups were observed^[@CR63]^. The only study to date examining white matter microstructure in medication-naïve and minimally treated patients found a shared increase in MD in a large number of white matter tracts across diagnostic categories, but showed that patients with first episode BD had decreased FA in the cingulum, internal capsule, and posterior brain regions that was not evident in first episode schizophrenia.^[@CR64]^

Functional MRI studies {#Sec7}
----------------------

### Task functional MRI {#Sec8}

A total of thirteen studies, all in chronically medicated patients, have directly contrasted functional activation patterns in BD and schizophrenia using various tasks (Table [3](#Tab3){ref-type="table"}). In working memory tasks, studies largely observe engagement of the same brain networks in healthy controls and patients across the psychosis spectrum, but find alterations in activation patterns within those networks. A graded pattern of group differences in the amplitude of the BOLD signal has been reported in several studies, with the greatest alteration typically reported in schizophrenia, and more subtle or lack of abnormalities in BD.^[@CR65]--[@CR67]^ Findings are more inconsistent, with both hypo- and hyper-activation reported, which may be explained by different, but overlapping, inverted u-shaped curves of activation depending on task difficulty^[@CR68]^ across the psychosis spectrum, with less abnormal patterns of activation in BD compared to schizophrenia. Alternatively, it is possible that these patterns of differential activation could represent compensatory processes or secondary effects of primary changes in signal processing. Greater task related alterations in schizophrenia compared to BD were also reported in a verbal fluency task,^[@CR69]^ but not a sentence completion task,^[@CR70]^ or emotionally salient memory tasks,^[@CR71],\ [@CR72]^ the latter appearing more altered in BD than schizophrenia. Furthermore, activation during reward anticipation in the ventral striatum appears decreased in schizophrenia, but not patients with BD in a manic state.^[@CR73]^ The authors speculated that striatal dopamine dysfunction, which could be clinically expressed as anhedonia, may be underlying their finding.Table 3Studies examining task activationAuthorYearn (HC/SZ/SAD/BD)Bipolar subtypeIllness durationMedication statusTeslaTaskDesignMain findingsMcIntosh *et al.* ^[@CR70]^200837/27/0/42ChronicMedicated1.5Hayling sentence completion testBlockBD \> HC activation in VLPFC, striatum and caudate. SZ \< HC in the DLPFCHamilton *et al.* ^[@CR131]^200938/20/0/21ChronicMedicated3Visual working memoryBlockHC \> SZ in activation in inferior frontal gyrus and DLPFC. HC \> BD in activation in occipital regions, SZ \> BD in precentral and postcentral gyrus, medial frontal gyrus and parietal regionsCostrafreda *et al.* ^[@CR132]^200948/39/0/28ChronicMedicated1.5Phonological letter fluencyBlockSZ \> HC = BD in activation in inferior frontal cortexWhalley *et al.* ^[@CR71]^200914/15/0/14ChronicMedicated1.5Emotionally salient memoryBlockBD \> HC \> SZ in left hippocampus, BD \> HC in posterior cingulate, STG and precentral gyrus. BD \> SZ in posterior cingulate, superior temporal sulcus, precentral gyrus. SZ \< HC in amygdalaHall *et al.* ^[@CR133]^200914/15/0/14ChronicMedicated1.5Face/name encode and retrieveBlockHC = BD \> SZ in activation of anterior right hippocampus during encode, BD \< SZ = HC in activation of left DLPFC during encode. SZ \> BD in DMPFC activation during retrieval, SZ \> HC in DLPFC activation during retrievalMilanovic *et al.* ^[@CR66]^201119/10/0/12PChronicMedicated1.5n-BackBlockSZ \> HC = BD activation in the MPFC region of interest, but no group differences in the DLPFC region of interestCostrafreda *et al.* ^[@CR69]^201140/32/0/32ChronicMedicated1.5Phonological letter fluencyBlockSZ \> BD \> HC activation in anterior cingulate, middle frontal gyrus, and putamen. SZ \> BD = HC superior, middle, and inferior frontal gyrus; SZ = BD \> HC in precuneus, posterior cingulate, and angular gyrusMorris *et al.* ^[@CR72]^201215/12/0/13ChronicMedicated3Emotionally salient memoryBlockBD \> SZ \> HC in emotion downregulation in the prefrontal cortex; BD = SZ \> HC in emotion upregulation in prefrontal cortexPalaniyappan *et al.* ^[@CR134]^201334/34/0/20PChronicMedicated3n-BackBlockHC \> SZ in degree centrality in frontal lobe, STG and insula, HC \> BD in degree centrality in insula, SZ \> HC in hippocampus, thalamus, and fusiform gyrus, BD \> HC hippocampus, thalamus, and caudateBrandt *et al.* ^[@CR65]^2014100/86/14/100P/NPChronicMedicated1.5n-BackBlockSZ \> BD \> HC in activation in the dorsolateral and ventrolateral PFC, premotor cortex and parietal cortex; HC \> BD \> SZ in inferior frontal gyrus, inferior parietal cortex, STG, and precuneusWu *et al.* ^[@CR67]^201429/36/0/20ChronicMedicated3n-BackBlockSZ \> BD \> HC in hyperactivity in the PCC and MPFCZhang *et al.* ^[@CR135]^201521/17/0/17PChronicMedicated3self-reflection taskBlockHC \> BD in PCC precuneus activation during other vs. self-contrastHagele *et al.* ^[@CR73]^201554/44/0/13ChronicMedicated1.5Monetary incentive delaySZ showed less ventral striatal activation compared to HC = BD during reward anticipation. No group differences in loss anticipation*HC* healthy control, *BD* bipolar disorder, *SZ* schizophrenia, *SAD* schizoaffective disorder, *P* psychotic bipolar disorder, *NP* non-psychotic bipolar disorder, *PFC* prefrontal cortex, *DLPFC* dorsolateral prefrontal cortex, *DMPFC* dorsomedial prefrontal cortex, *MPFC* medial prefrontal cortex, *VLPFC* ventrolateral prefrontal cortex, *STG* superior temporal gyrus, *PCC* posterior cingulate cortex

### Resting state functional MRI {#Sec9}

Investigation of functional connectivity at rest has become increasingly popular, in part because task performance differences between groups need not be accounted for in this paradigm.^[@CR74]^ An activation likelihood estimation meta-analysis of whole brain resting state studies in schizophrenia suggests decreased activity in the medial prefrontal cortex, left hippocampus, posterior cingulate cortex and precuneus (all areas of the brain that are typically conceptualized as part of the default mode network^[@CR75]^), as well as increased activity in the lingual gyrus.^[@CR76]^ A recent review attempting to reconcile methodological differences in schizophrenia studies suggested increased functional connectivity to be a replicated finding.^[@CR77]^ In a qualitative systematic review Vargas and colleagues reported aberrant resting state connectivity in between frontal and meso-limibic areas in BD when compared to controls.^[@CR78]^

All of the sixteen resting state studies comparing connectivity across diagnostic groups included here were conducted in patients who were medicated at the time of scanning (Table [4](#Tab4){ref-type="table"}). The default mode network, a large scale brain network that is more active at rest and has been implicated in self-referential thinking, is perhaps the most widely studied. An early report in acutely ill patients with schizophrenia and BD identified the medial prefrontal cortex as major locus of shared abnormality, with BD being characterized by reduced default mode network connectivity to the hippocampus and fusiform gyrus as well as increased connectivity with the primary visual cortex, and schizophrenia being characterized by abnormal recruitment of the frontal polar cortex and the basal ganglia.^[@CR79]^ The largest study to date examining default mode network connectivity with ICA reported connectivity reductions in the medial prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex and precuneus across the psychosis spectrum, but also found that selective nodes within the network appear to be differentially affected in schizophrenia and BD.^[@CR80]^ The same group also reported aberrant connectivity between the default mode and a fronto-occipital network as shared illness feature in schizophrenia and BD, whereas increased connectivity between fronto-temporal and mesolimbic regions was only evident in BD, and decreased connectivity between sensory-motor and mesolimbic areas was limited to schizophrenia.^[@CR81]^ Others report within and between network connectivity decreases within a cingulo-opercular network and between a cingulo-opercular and cerebellar network that are shared across illnesses, decreased connectivity between the cingulo-opercular and salience network in BD only, and decreased connectivity between cingulo-opercular and fronto-parietal network in schizophrenia only. Notably, default mode network connectivity was not reported abnormal.^[@CR82]^ Similarly, Baker and colleagues reported resting state connectivity disruptions of cortical association networks, preferentially the frontoparietal control network, but not default mode network abnormalities, in schizophrenia and BD.^[@CR83]^ Table 4Resting state studiesAuthorYearn (HC/SZ/SAD/BD)Bipolar subtypeIllness durationMedication statusAreas of interestTeslaScan (min)eyes open/closedAnalysisMain findingsOngur *et al.* ^[@CR79]^201015/7/7/17Acutely illMedicatedDefault mode network310OpenICAMixed increase and decrease in DMN connectivity in both SZ and BD compared to HCChai *et al.* ^[@CR136]^201115/16/0/14ChronicMedicatedMedial prefrontal cortex310OpenSeedBD \> SZ \> HC in ventrolateral prefrontal cortex and insula connectivity; HC \> SZ \> BD in DLPFC connectivityMeda *et al.* ^[@CR81]^2012118/70/0/64PChronicMedicated16 Large scale networks35.25OpenICAHC \> SZ = BD in fronto-occipital and anterior DMN, HC = BD \> SZ in meso/paralimbic and sensory-motor network, BD \> HC in Fronto-temporal/paralimbic and meso/paralimbicMamah *et al.* ^[@CR82]^201333/25/0/35ChronicMedicatedFive large scale networks313.7ClosedSeedHC \> BD = SZ in cingulo-opercular networkLiu *et al.* ^[@CR85]^201418/18/0/18ChronicMedicatedPrefrontal cortex, amygdala3ClosedSeedBD = SZ mixed increase and decrease in connectivity between amygdala subregions and the prefrontal cortex compared to HCMeda *et al.* ^[@CR80]^2014324/269/0/300PChronicMedicatedDefault mode networkICAHC \> BD \> SZAnticevic *et al.* ^[@CR84]^2014146/90/0/73P/NPChronicMedicatedThalamus35.25OpenSeedMixed increase and decrease in connectivity in SZ and BD compared to HC; BD show less cerebellar dysconnectivity than SZKnochel *et al.* ^[@CR38]^201421/21/0/21ChronicMedicatedHippocampus313.3SeedNo significant differences when all three groups are comparedRashid *et al.* ^[@CR137]^201461/60(SZ/ SAD)/0/38P/NPChronicMedicated49 Large scale networks35.25OpenDynamic ICAHC \> BD = SZ in number of transitions between statesArgyelan *et al.* ^[@CR87]^201432/18/0/19P/NPChronicMedicatedWhole brain connectivity, caudate35ClosedSeedSZ \< BD \< HC in global connectivity, specifically thalamus, paracingulate, caudate, fusiform and lingual gyrusBaker *et al.*JT^[@CR83]^2014100/28/32/40PChronicMedicated17 Large scale networks36.2OpenSeedHC \> BD = SZ in frontoparietal networkMeda *et al.* ^[@CR138]^2015242/220/147/180PChronicMedicatedWhole brain35OpenALFFMixed increase and decrease in ALFF in all diagnostic groupsDu *et al.* ^[@CR139]^201520/20/33/20ChronicMedicated12 Large scale networks35OpenICADiscriminative regions included frontal, parietal, precuneus, cingulate, supplementary motor, cerebellar, insula and supramarginal corticesAnticevic *et al.* ^[@CR140]^201556/73/0/73P/NPChronicMedicatedVentral ACC35.25OpenSeedHC \> SZ = BDHager *et al.* ^[@CR141]^2016156/107/98/125PChronicMedicatedWhole brain35Multiple time scalesSZ \< HC in complexity in hypothalamus, BD \< HC in complexity in left inferior occipital, right precentral and left superior parietal. HC \> SZ = SAD = in complexity PFCSkatun *et al.* ^[@CR142]^2016196/60/11/43ChronicMedicated35.3OpenEigenvector centrality mappingHC \> SZ in global connectivity in sensory regions, HC \> SZ = BD in subcortical regions; SZ \> BD \> HC in connectivity in frontal and parietal areas*HC* healthy control, *BD* bipolar disorder, *SZ* schizophrenia, *SAD* schizoaffective disorder, *P* psychotic bipolar disorder, *NP* non-psychotic bipolar disorder, *ICA* independent components analysis, *ALFF* amplitude of low frequency fluctuations, *ACC* anterior cingulate cortex, *PFC* prefrontal cortex, *DLPFC* dorsolateral prefrontal cortex, *DMN* default mode network

Resting state studies of non-neocortical structures revealed distinct patterns of thalamic^[@CR84]^ and amygdalar^[@CR85]^ dysconnectivity in schizophrenia and BD, but no differences across diagnostic groups in hippocampal^[@CR38],\ [@CR86]^ connectivity. Examining connectivity across the entire brain with global brain connectivity, a measure that computes connectivity strength of every region of the brain with every other region of the brain, was reported to be lower in schizophrenia than in healthy controls, whereas patients with BD had intermediate global connectivity strength that was significantly different from both patients with schizophrenia and healthy controls.^[@CR87]^

Magnetic resonance spectroscopy studies {#Sec10}
---------------------------------------

There is substantial evidence that neurometabolite levels are altered in both schizophrenia and BD. A meta-analysis pooling data from 146 studies suggests decreases in NAA in the frontal lobe, hippocampus, thalamus, and basal ganglia in schizophrenia, but only in the basal ganglia and frontal lobe in BD.^[@CR88]^ Another meta-analysis summarizing findings of glutamatergic abnormalities across 28 studies in schizophrenia revealed a decrease in medial frontal glutamate compared with healthy controls,^[@CR89]^ but the majority of studies were conducted in medicated patients. Contrastingly, several reports do suggest an elevation of glutamatergic indices in unmedicated patients with schizophrenia in the medial prefrontal cortex, striatum, and hippocampus.^[@CR90]--[@CR93]^ A smaller meta-analysis in BD including nine studies measuring Glx (a combination of glutamate and glutamine) across different areas of the brain, suggested that this metabolite may be higher in patients with BD compared to controls, irrespective of medication status.^[@CR94]^ Taken together, it appears that some of the neurometabolite alterations, specifically decreased NAA in the frontal cortex and basal ganglia may be shared across the illness spectrum, whereas others may not.

However, studies directly contrasting neurometabolites in BD and schizophrenia are sparse. All of these studies used single voxel^1^ H-MRS placed in cortical areas of the brain and were conducted in chronically ill patients who were medicated at the time of assessment, most commonly with very small sample sizes (Table [5](#Tab5){ref-type="table"}). Molina and colleagues were the first to report that NAA/Cr decreases in the left, but not the right dorsolateral prefrontal cortex were greater in schizophrenia than in BD, with no Cho/Cr abnormalities appreciated in either group.^[@CR95]^ Findings were partially replicated by Kalayci and colleagues, who reported a universal decrease in left and right dorsolateral prefrontal cortex NAA/Cr across diagnostic groups, but a decrease in Cho/Cr only in BD and schizoaffective disorder, but not schizophrenia when compared to controls.^[@CR96]^ Anterior cingulate cortex metabolite measurements at 1.5 Tesla were suggestive of elevations of Cho/Cr in schizophrenia only without detectable abnormalities in NAA/Cr across groups.^[@CR97]^ However, because of a later report of decreased Cr levels in acutely ill patients with schizophrenia but not BD, it is unclear if findings are attributable to Cr alterations rather than Cho or NAA changes.^[@CR98]^ In the left Heschl's gyrus, Glu, NAA, and inositol levels were found to be decreased in BD, but not in schizophrenia when compared to healthy controls, while no metabolite abnormalities in either diagnostic group were detected in the right Heschl's gyrus, suggesting a lateralized abnormality in the dominant hemisphere.^[@CR99]^ Only one study to date has examined GABA, with reports of perisylvian GABA elevations in patients with schizophrenia, but not those with BD, when compared to healthy controls.^[@CR100]^ Table 5Studies examining magnetic resonance spectroscopy (MRS)AuthorYearn (HC/SZ/ SAD/ BD)Bipolar subtypeIllness durationMedication statusArea of interestMRSSequenceTeslaMain findingsMolina *et al.* ^[@CR95]^200710/11/0/13P/NPChronicMedicatedDLPFCSVPRESS1.5NAA/Cr decreased in SZ and BD No abnormalities in Cho/Cr in either group compared to HCCrespo *et al.* ^[@CR97]^200815/14/0/17NPChronicMedicateddACCSVPRESS1.5NAA/Cho SZ \< HC and BD; Cho/Cr SZ \> HC and BD; NAA/Cr no group differencesOngur *et al.* ^[@CR98]^200922/8/7/15PChronicMedicatedACC/POCSVPRESS4Cr HC = BD \> SZ in both voxelsOngur *et al.* ^[@CR143]^201020/15/0/15PChronicMedicatedACC/ POCSVPRESS4Numerically shortened T2 relaxation times in BD and SZKalayci *et al.* ^[@CR96]^201215/15/15/15ChronicMedicatedDLPFCSVPRESS1.5NAA HC \> BD, SZ, SAD; Cho HC \> BD, SAD; Cr C \> BD, SAD, SZAtagun *et al.* ^[@CR99]^201530/30/0/28ChronicMedicatedHeschl's gyrusSVPRESS3Glu, NAA, and Cr HC \> BD in left hemisphere; no group differences in right hemisphereAtagun *et al.* ^[@CR100]^201630/25/0/48ChronicMedicatedPerisylvian structuresSVMEGA-PRESS3GABA SZ \> BD = HC*HC* healthy control, *BD*, bipolar disorder, *SZ* schizophrenia, *SAD* schizoaffective disorder, *P* psychotic bipolar disorder, *NP* non-psychotic bipolar disorder, *DLPFC* dorsolateral prefrontal cortex, *ACC* anterior cingulate cortex, *dACC* dorsal anterior cingulate cortex, *POC* parieto-occipital cortex, *SV* single voxel, *PRESS* point resolved spectroscopy sequence, *NAA* N-acetyl-aspartate, *Cr* creatine, *Cho* choline, *Glu* glutamate, *GABA* gamma-aminobutyric acid

Imaging-genetic studies {#Sec11}
-----------------------

Eight studies, all in medicated patients, have examined relationships between imaging and genetic markers across the illness spectrum (Table [6](#Tab6){ref-type="table"}). In verbal fluency tasks, significant diagnosis by genotype interactions with task related activations were observed for Neuregulin 1,^[@CR101]^ disrupted in Schizophrenia Gene 1 (DISC 1^[@CR102]^), and the [d]{.smallcaps}-amino acid oxidase (See ref. [@CR103]) gene. Interestingly, a modest relationship between white matter volume and a number of schizophrenia risk genes was found across the psychosis spectrum and in healthy controls, suggesting that cumulative genetic risks may help explain the extent of observed white matter alterations,^[@CR104]^ but other risk genes did not show such relationships.^[@CR105]^ Table 6Imaging genetic studiesAuthorYearn (HC/SZ/SAD/BD)Bipolar subtypeIllness durationMedication statusGenesImaging modalityDesignAnalysis typeTeslaMain findingsMechelli *et al.* ^[@CR101]^200845/41/0/29ChronicMedicatedNeuregulin 1Verbal fluency task fMRIBlock designFull factorial ANOVA1.5HC \> BD = SZ in activation in the angular gyrus. Significant diagnosis x genotype interaction in prefrontal cortex activationPrata *et al.* ^[@CR102]^201153/44/0/35P/NPChronicMedicatedDISC 1Verbal fluency task fMRIBlock designFull factorial ANOVA1.5HC \< SZ in activation in middle frontal gyrus, no differences between HC and BD. Group × genotype interaction (HC and SZ) in left superior frontal gyrus activationPapagni *et al.* ^[@CR103]^201148/40/0/33ChronicMedicatedDAAOVerbal fluency task fMRIBlock designFull factorial ANOVA1.5HC \> SZ in activation of the PCC, no group differences between SZ and BD. Diagnosis x genotype interaction in precuneus and PCCTesli *et al.* ^[@CR144]^2013123/52/9/66PChronicMedicatedCACNAC1CEmotionally salient fMRIBlock designFull factorial ANOVA1.5No significant diagnosis x genotype interaction in all groupsKittel-Schneider *et al.* ^[@CR45]^201518/23/0/30P/NPFEMedicatedDGKHStructural MRIROI (manual tracing)ANOVA1.5HC \> BD \> SZ in left amygdala volume. Significant gene × volume effect in right amygdalaOertel-Knochel *et al.* ^[@CR104]^201550/24/0/20ChronicMedicated7 SZ risk SNPsStructural MRIVBMHierarchal regression analyses3HC \> SZ  = BD in white matter volume, association between risk genes and white matter volume found only in HC, not SZ or BDMallas *et al.* ^[@CR105]^2016124/63/0/42NPChronicMedicatedCACNAA1CDiffusion tensor imagingTBSSANOVA1.5No genotype main effect, no group by genotype interactionTandon *et al.* ^[@CR145]^2016123/139/90/160PChronicMedicatedLarge number of SNPsStructural MRIFree surferPara-ICA3Four structural and three genetic components that showed overlapping relationships with the disease risk genes across illnesses*HC* healthy control, *BD* bipolar disorder, *SZ* schizophrenia, *SAD* schizoaffective disorder, *P* psychotic bipolar disorder, *NP* non-psychotic bipolar disorder, *FE* first episode, *ROI* region of interest, *TBSS* tract based spatial statistics, *ANOVA* analysis of variance, *ICA* independent components analysis, *PCC* posterior cingulate cortex

Discussion {#Sec12}
==========

In this systematic review, we sought to summarize converging and distinct neural signatures in schizophrenia and BD. Structural neuroimaging studies suggest white matter integrity deficits that are consistent, both in magnitude and spatial extent, across the psychosis spectrum, while gray matter reductions, especially those that are cortical, appear more widespread in schizophrenia compared to BD. Similarly, spectroscopy studies in cortical gray matter report evidence of decreased neuronal integrity in both disorders, but not enough data exists to draw firm conclusions as to differences in magnitudes and spatial distribution between illnesses. On a functional level, findings are inconsistent, possibly because of small sample sizes in many of the studies. Functional MRI studies using task paradigms typically report engagement of the same brain networks in healthy controls and patients across the psychosis spectrum, but find differential extent of alterations in magnitude of task related activation between illnesses depending on the task paradigm. The larger resting state connectivity studies are inconsistent as to abnormalities in the default mode network, but it appears that decreased fronto-parietal network connectivity may be a shared feature across the psychosis spectrum. The very limited imaging-genetic literature suggests a relationship between psychosis risk genes and brain structure, and possible gene by diagnosis interaction effects on functional imaging markers.

Our work needs to be considered in context of several limitations. We performed a systematic review, but did not perform quantitative assessments using meta-analytic techniques which could be informative in future work. We did not do separate analyses in schizophreniform disorder or schizoaffective disorder due to a lack of studies investigating these as a distinct disease category (schizoaffective disorder is most commonly grouped under schizophrenia). We decided not to include ultra-high risk subjects as conversion rates to psychotic illness is reported to be 30% or less,^[@CR106]^ and psychotic depression due to the paucity of studies including this disease category.

It is important to note that the vast majority of studies have been conducted in chronically ill, medicated patients, which precludes us from being able to disentangle intrinsic illness characteristics from changes attributable to disease progression and exposure to psychotropic medications. While the existing literature suggests some shared and some distinct neural markers in across the psychosis spectrum, it will be imperative to conduct large, well designed, multi-modal neuroimaging studies in medication-naïve first episode patients that will be followed longitudinally over the course of their illness in an effort to advance our understanding of disease mechanisms and to resolve the illness dichotomy vs. illness spectrum debate. But because this type of studies are notoriously difficult to conduct, and sample sizes are typically fewer than 50 subjects,^[@CR107]--[@CR112]^ a potential alternative strategy may be to obtain very large, multi-site datasets and attempt to mitigate medication confounds with statistical adjustments.

Methods {#Sec13}
=======

Eligibility criteria {#Sec14}
--------------------

Studies were included if they presented original data published between January 2005 and December 2016 (last search December 9th 2016), compared individuals with BD and schizophrenia/schizoaffective disorder and healthy controls. Studies were not included when the healthy control group was genetically related to the patient groups. Studies published in languages other than English, post mortem studies, non-human studies, and review articles were excluded. We only included trials with ten or more healthy subjects, aged 18 or older. Studies expressively including subjects with comorbid substance use disorders, neurological or genetic diseases, or intellectual disabilities were not considered. When a single study was published in several articles, the article reporting the largest group was used. Articles that did not explicitly compare imaging findings between diagnostic groups were excluded as well.

Literature search {#Sec15}
-----------------

BB and NVK performed a literature search in PubMed including subjects across the psychosis spectrum using the following key words: (Schizophrenia AND bipolar disorder) AND (gray matter OR morphometry OR VBM OR volume OR white matter OR DTI OR magnetic resonance spectroscopy OR MRS OR functional MRI OR resting state). The reference lists of included studies, as well as relevant meta-analyses were inspected for additional eligible publications.

Study selection {#Sec16}
---------------

After removal of duplicate articles, BB and NVK screened titles and abstracts retrieved from the search and selected potentially eligible studies for full text review. Both authors applied eligibility criteria, and a list of eligible full text articles was developed through consensus. Full text articles were then downloaded or requested from the university library and assessed for eligibility. Figure [1](#Fig1){ref-type="fig"} describes the study selection process and outcome.

Data extraction {#Sec17}
---------------

We extracted the following data from each study: name of first author, year of publication, number of participants per diagnostic category, illness duration, mood state, use of psychotropic medications, data acquisition parameters, magnetic field strength, data processing parameters, main study outcomes.
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